Clinicopathologic and11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer’s disease spectrum
Open accessThe DOI matches its Crossref record; 71 of the 72 references it cites were found in a registry or an index.
Abstract
Thal amyloid phase, which describes the pattern of progressive amyloid-β plaque deposition in Alzheimer's disease, was incorporated into the latest National Institute of Ageing - Alzheimer's Association neuropathologic assessment guidelines. Amyloid biomarkers (positron emission tomography and cerebrospinal fluid) were included in clinical diagnostic guidelines for Alzheimer's disease dementia published by the National Institute of Ageing - Alzheimer's Association and the International Work group. Our first goal was to evaluate the correspondence of Thal amyloid phase to Braak tangle stage and ante-mortem clinical characteristics in a large autopsy cohort. Second, we examined the relevance of Thal amyloid phase in a prospectively-followed autopsied cohort who underwent ante-mortem (11)C-Pittsburgh compound B imaging; using the large autopsy cohort to broaden our perspective of (11)C-Pittsburgh compound B results. The Mayo Clinic Jacksonville Brain Bank case series (n = 3618) was selected regardless of ante-mortem clinical diagnosis and neuropathologic co-morbidities, and all assigned Thal amyloid phase and Braak tangle stage using thioflavin-S fluorescent microscopy. (11)C-Pittsburgh compound B studies from Mayo Clinic Rochester were available for 35 participants scanned within 2 years of death. Cortical (11)C-Pittsburgh compound B values were calculated as a standard uptake value ratio normalized to cerebellum grey/white matter. In the high likelihood Alzheimer's disease brain bank cohort (n = 1375), cases with lower Thal amyloid phases were older at death, had a lower Braak tangle stage, and were less frequently APOE-ε4 positive. Regression modelling in these Alzheimer's disease cases, showed that Braak tangle stage, but not Thal amyloid phase predicted age at onset, disease duration, and final Mini-Mental State Examination score. In contrast, Thal amyloid phase, but not Braak tangle stage or cerebral amyloid angiopathy predicted (11)C-Pittsburgh compound B standard uptake value ratio. In the 35 cases with ante-mortem amyloid imaging, a transition between Thal amyloid phases 1 to 2 seemed to correspond to (11)C-Pittsburgh compound B standard uptake value ratio of 1.4, which when using our pipeline is the cut-off point for detection of clear amyloid-positivity regardless of clinical diagnosis. Alzheimer's disease cases who were older and were APOE-ε4 negative tended to have lower amyloid phases. Although Thal amyloid phase predicted clinical characteristics of Alzheimer's disease patients, the pre-mortem clinical status was driven by Braak tangle stage. Thal amyloid phase correlated best with (11)C-Pittsburgh compound B values, but not Braak tangle stage or cerebral amyloid angiopathy. The (11)C-Pittsburgh compound B cut-off point value of 1.4 was approximately equivalent to a Thal amyloid phase of 1-2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For amyloid imaging, where over a decade of data are available, different ligands, methods of image acquisition, and image processing can result in different thresholds when compared to neuropathologic standards [21,22,196].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent studies suggest that NFT pathology closely correlates with neurodegeneration and cognitive decline [1, 2].”
From Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology (2016) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“supports recent evidence that tau may play an early pathological role in Alzheimer’s disease129–131”
From Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (2019) · cites this paper as [129]
The cited source says what the claim attributes to it.
In the citing paper
“Imaging-to-autopsy comparison studies have established that amyloid positron emission tomography (PET) is a valid in vivo surrogate for Aβ deposits (in brain parenchyma/vessel walls) [17–24].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“A typical cut point used for 11C Pittsburgh compound B approximately labels individuals with Thal phase 0–1 normal and individuals with Thal phase 2–5 abnormal [21].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282 · cited 1×
“Ante-mortem clinical history for age at onset of cognitive symptoms, education, and Mini-Mental State Examination (MMSE) score (Folstein et al., 1975) was retrospectively abstracted from clinical reports for the Mayo Clinic Jacksonville series, with investigators blinded to Thal amyloid phase.”
MethodHirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · Brain and nerve · Cited by 21,038
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J. M., & Wouters, E. J. M. (2016) · Gerontology · doi:10.1159/000430949 · Cited by 19,690
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. (2015) · Gerontology · doi:10.1159/000362720 · Cited by 18,909
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · cited 4×
“CSF) have been included in NIA-AA clinical diagnostic guidelines for Alzheimer’s disease dementia (Albert et al., 2011; Jack et al., 2011; McKhann et al., 2011).”
BackgroundMethodInfluentialSelf-citationNeuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 7×
“A Braak NFT stage of 5IV is consistent with NFTs restricted to limbic regions and not yet involving cortical regions (Braak and Braak, 1991).”
BackgroundMethodInfluentialAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 2×
“CSF) have been included in NIA-AA clinical diagnostic guidelines for Alzheimer’s disease dementia (Albert et al., 2011; Jack et al., 2011; McKhann et al., 2011).”
MethodSelf-citationSperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · cited 2×
“well as preclinical stages of the disease (Jack et al., 2011; McKhann et al., 2011; Sperling et al., 2011).”
BackgroundMethodSelf-citationDiagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Self-citationMirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496 · cited 3×
“The Mayo Clinic Jacksonville Brain Bank case series (n = 3618) was selected regardless of ante-mortem clinical diagnosis and neuropathologic co-morbidities, and all assigned Thal amyloid phase and Braak tangle stage using thioflavin-S fluorescent microscopy.”
BackgroundMethodPhases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490 · cited 10×
“Both proteins are considered to develop in a topographic pattern that can be stereotypically assessed using Thal amyloid phase for amyloid-b plaques (Thal et al., 2002) and Braak NFT”
BackgroundMethodInfluentialHyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092 · cited 9×
“Thal amyloid phase was recently incorporated into the latest NIA-Alzheimer’s Association’s (NIA-AA) neuropathologic assessment guidelines (Hyman et al., 2012; Montine et al., 2012), which is of particular importance as amyloid biomarkers (e.g. PET and amyloid-b CSF) have been included in NIA-AA…”
BackgroundMethodInfluentialSelf-citationMontine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0910-3 · Cited by 2,894 · cited 5×
“…brains by retrospectively assessing senile plaque quantification of neocortex (i.e. midfrontal, inferior parietal or superior temporal cortex) and hippocampus using thioflavin-S staining results as supported in the latest NIA-AA recommendations (Hyman et al., 2012; Montine et al., 2012).”
BackgroundMethodInfluentialSelf-citationAlbert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2013) · Focus · doi:10.1176/appi.focus.11.1.96 · Cited by 2,621
Self-citationDiagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499
Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
Fillenbaum, G. G., & Heyman, A. (2002) · Principles and Practice of Geriatric Psychiatry · doi:10.1002/0470846410.ch42(iii · Cited by 2,410
Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years
Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318232a379 · Cited by 2,194 · cited 1×
“The initial sites of neuropathologic insults greatly differ between the two proteins with amyloid-b found in the cortex 10–15 years before cognitive decline (Price and Morris, 1999) and NFTs found in brainstem structures of individuals in their 20’s and 30’s (Braak et al., 2011).”
BackgroundNelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050
Jack, C. R., Albert, M. S., Knopman, D. S., McKhann, G. M., Sperling, R. A., Carrillo, M. C., Thies, B., & Phelps, C. H. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.004 · Cited by 2,042
Self-citationImaging β-amyloid burden in aging and dementia
Rowe, C. C., Ng, S., Ackermann, U., Gong, S. J., Pike, K., Savage, G., Cowie, T. F., Dickinson, K. L., Maruff, P., Darby, D., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000261919.22630.ea · Cited by 1,104
Jack, C. R., Lowe, V. J., Weigand, S. D., Wiste, H. J., Senjem, M. L., Knopman, D. S., Shiung, M. M., Gunter, J. L., Boeve, B. F., Kemp, B. J., et al. (2009) · Brain · doi:10.1093/brain/awp062 · Cited by 1,099
Self-citationMurray, M. E., Graff-Radford, N. R., Ross, O. A., Petersen, R. C., Duara, R., & Dickson, D. W. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70156-9 · Cited by 972 · cited 5×
“Atypical distributions of NFT pathology are known to disproportionately affect neocortex relative to limbic regions and vice versa in 25% of Alzheimer’s disease cases (Galton et al., 2000; Alladi et al., 2007; Murray et al., 2011; Whitwell et al., 2012).”
BackgroundMethodInfluentialSelf-citationJack, C. R., Lowe, V. J., Senjem, M. L., Weigand, S. D., Kemp, B. J., Shiung, M. M., Knopman, D. S., Boeve, B. F., Klunk, W. E., Mathis, C. A., et al. (2008) · Brain · doi:10.1093/brain/awm336 · Cited by 958
Self-citationPost-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Lopresti, B. J., Ziolko, S., Bi, W., Paljug, W. R., et al. (2008) · Brain · doi:10.1093/brain/awn016 · Cited by 933 · cited 8×
“, 1991), both of which have fibrillar forms of amyloid that bind the fluorescent analogue of PiB or radiolabelled PiB (Lockhart et al., 2007; Ikonomovic et al., 2008).”
BackgroundInfluentialTDP‐43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease
Amador‐Ortiz, C., Lin, W., Ahmed, Z., Personett, D., Davies, P., Duara, R., Graff‐Radford, N. R., Hutton, M. L., & Dickson, D. W. (2007) · Annals of Neurology · doi:10.1002/ana.21154 · Cited by 916 · cited 2×
“TAR DNA binding protein 43 (TARDBP, previously known as TDP-43) positivity (Amador-Ortiz et al., 2007) and Lewy body disease type (Uchikado et al.”
BackgroundMethodSelf-citationNeuropathology of Cognitively Normal Elderly
Knopman, D. S., Parisi, J. E., Salviati, A., Floriach-Robert, M., Boeve, B. F., Ivnik, R. J., Smith, G. E., Dickson, D. W., Johnson, K. A., Petersen, L. E., et al. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.11.1087 · Cited by 674 · cited 2×
“…now been many studies of the association between cognition and amyloid-b accumulation at different points along the Alzheimer’s disease spectrum (Morris et al., 1996; Schmitt et al., 2000; Knopman et al., 2003; Petersen et al., 2006; Price et al., 2009; Maarouf et al., 2011; Mathis et al., 2013).”
BackgroundSelf-citationNeuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease
Price, J. L., McKeel, D. W., Buckles, V. D., Roe, C. M., Xiong, C., Grundman, M., Hansen, L. A., Petersen, R. C., Parisi, J. E., Dickson, D. W., et al. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.04.002 · Cited by 661 · cited 2×
“…now been many studies of the association between cognition and amyloid-b accumulation at different points along the Alzheimer’s disease spectrum (Morris et al., 1996; Schmitt et al., 2000; Knopman et al., 2003; Petersen et al., 2006; Price et al., 2009; Maarouf et al., 2011; Mathis et al., 2013).”
BackgroundSelf-citationIdentification of normal and pathological aging in prospectively studied nondemented elderly humans
Dickson, D. W., Crystal, H. A., Mattiace, L. A., Masur, D. M., Blau, A. D., Davies, P., Yen, S.-H., & Aronson, M. K. (1992) · Neurobiology of Aging · doi:10.1016/0197-4580(92)90027-u · Cited by 643 · cited 1×
“The thioflavin-S staining protocol we used for these studies is sensitive to all senile plaque types (e.g. diffuse, cored, and neuritic) (Dickson et al., 1992), which were each included with a truncated maximum of 50 plaques per 3 mm2 using a 10 objective (Supplementary Fig.”
MethodSelf-citationTwo-year follow-up of amyloid deposition in patients with Alzheimer's disease
Engler, H., Forsberg, A., Almkvist, O., Blomquist, G., Larsson, E., Savitcheva, I., Wall, A., Ringheim, A., Langstrom, B., & Nordberg, A. (2006) · Brain · doi:10.1093/brain/awl178 · Cited by 617 · cited 2×
“PiB-PET binding in patients with Alzheimer’s disease dementia, however, does not increase appreciably over 2 years; (Engler et al., 2006) and annual change within 1 year does not differ among cognitively normal, mild cognitive impairment and Alzheimer’s disease dementia patients (Jack et al.”
BackgroundNeuropathologic Features of Amnestic Mild Cognitive Impairment
Petersen, R. C., Parisi, J. E., Dickson, D. W., Johnson, K. A., Knopman, D. S., Boeve, B. F., Jicha, G. A., Ivnik, R. J., Smith, G. E., Tangalos, E. G., et al. (2006) · Archives of Neurology · doi:10.1001/archneur.63.5.665 · Cited by 616 · cited 2×
“…now been many studies of the association between cognition and amyloid-b accumulation at different points along the Alzheimer’s disease spectrum (Morris et al., 1996; Schmitt et al., 2000; Knopman et al., 2003; Petersen et al., 2006; Price et al., 2009; Maarouf et al., 2011; Mathis et al., 2013).”
BackgroundSelf-citationGalton, C. J. (2000) · Brain · doi:10.1093/brain/123.3.484 · Cited by 613 · cited 2×
“Atypical distributions of NFT pathology are known to disproportionately affect neocortex relative to limbic regions and vice versa in 25% of Alzheimer’s disease cases (Galton et al., 2000; Alladi et al., 2007; Murray et al., 2011; Whitwell et al., 2012).”
BackgroundMorris, J. C., Storandt, M., McKeel, D. W., Rubin, E. H., Price, J. L., Grant, E. A., & Berg, L. (1996) · Neurology · doi:10.1212/wnl.46.3.707 · Cited by 603 · cited 2×
“…now been many studies of the association between cognition and amyloid-b accumulation at different points along the Alzheimer’s disease spectrum (Morris et al., 1996; Schmitt et al., 2000; Knopman et al., 2003; Petersen et al., 2006; Price et al., 2009; Maarouf et al., 2011; Mathis et al.,…”
BackgroundFocal cortical presentations of Alzheimer's disease
Alladi, S., Xuereb, J., Bak, T., Nestor, P., Knibb, J., Patterson, K., & Hodges, J. R. (2007) · Brain · doi:10.1093/brain/awm213 · Cited by 581 · cited 2×
“Atypical distributions of NFT pathology are known to disproportionately affect neocortex relative to limbic regions and vice versa in 25% of Alzheimer’s disease cases (Galton et al., 2000; Alladi et al., 2007; Murray et al., 2011; Whitwell et al., 2012).”
BackgroundCrutch, S. J., Lehmann, M., Schott, J. M., Rabinovici, G. D., Rossor, M. N., & Fox, N. C. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70289-7 · Cited by 577
Bennett, D. A., Schneider, J. A., Wilson, R. S., Bienias, J. L., & Arnold, S. E. (2004) · Archives of Neurology · doi:10.1001/archneur.61.3.378 · Cited by 526 · cited 4×
“…recommendations for post-mortem diagnosis of Alzheimer’s disease, and is widely validated by clinicopathological studies that demonstrate strong associations with greater severity of cognitive decline (Duyckaerts et al., 1997; Bennett et al., 2004; Sabbagh et al., 2010; Nelson et al., 2012).”
BackgroundInfluentialImaging of amyloid burden and distribution in cerebral amyloid angiopathy
Johnson, K. A., Gregas, M., Becker, J. A., Kinnecom, C., Salat, D. H., Moran, E. K., Smith, E. E., Rosand, J., Rentz, D. M., Klunk, W. E., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21164 · Cited by 495 · cited 10×
“Given the predominance of cerebral amyloid angiopathy in the occipital lobe, visual grading of PiB-PET scans should be performed with the concept that greater occipital-to-global PiB ratio may occur in patients with Alzheimer’s disease dementia with suspected cerebral amyloid angiopathy (Johnson et al., 2007; Kantarci…”
BackgroundMethodInfluentialWhitwell, J. L., Dickson, D. W., Murray, M. E., Weigand, S. D., Tosakulwong, N., Senjem, M. L., Knopman, D. S., Boeve, B. F., Parisi, J. E., Petersen, R. C., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70200-4 · Cited by 419 · cited 2×
“Atypical distributions of NFT pathology are known to disproportionately affect neocortex relative to limbic regions and vice versa in 25% of Alzheimer’s disease cases (Galton et al., 2000; Alladi et al., 2007; Murray et al., 2011; Whitwell et al., 2012).”
BackgroundSelf-citation“Preclinical” AD revisited: Neuropathology of cognitively normal older adults
Schmitt, F. A., Davis, D. G., Wekstein, D. R., Smith, C. D., Ashford, J. W., & Markesbery, W. R. (2000) · Neurology · doi:10.1212/wnl.55.3.370 · Cited by 369
Alzheimer Disease With Amygdala Lewy Bodies: A Distinct Form of α-Synucleinopathy
Uchikado, H., Lin, W.-L., DeLucia, M. W., & Dickson, D. W. (2006) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/01.jnen.0000225908.90052.07 · Cited by 359 · cited 2×
“, 2007) and Lewy body disease type (Uchikado et al., 2006) was assessed using immunohistochemical methods, as previously described.”
MethodSelf-citationJack, C. R., Wiste, H. J., Weigand, S. D., Rocca, W. A., Knopman, D. S., Mielke, M. M., Lowe, V. J., Senjem, M. L., Gunter, J. L., Preboske, G. M., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70194-2 · Cited by 358 · cited 2×
“Using our pipeline we defined the threshold for PiB-positivity at the cut-off point that corresponded to a 90% sensitivity of clinically diagnosed Alzheimer’s disease subjects with an abnormal PET scan (Jack et al., 2014), which corresponds to a PiB-PET SUV ratio51.”
BackgroundMethodInfluentialSelf-citationMolecular Imaging With Pittsburgh Compound B Confirmed at Autopsy: A Case Report
Bacskai, B. J., Frosch, M. P., Freeman, S. H., Raymond, S. B., Augustinack, J. C., Johnson, K. A., Irizarry, M. C., Klunk, W. E., Mathis, C. A., DeKosky, S. T., et al. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.431 · Cited by 341 · cited 2×
“The Mayo Clinic Jacksonville Brain Bank case series (n = 3618) was selected regardless of ante-mortem clinical diagnosis and neuropathologic co-morbidities, and all assigned Thal amyloid phase and Braak tangle stage using thioflavin-S fluorescent microscopy.”
MethodYaar, M., Zhai, S., Pilch, P. F., Doyle, S. M., Eisenhauer, P. B., Fine, R. E., & Gilchrest, B. A. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119772 · Cited by 336 · cited 1×
“Amyloid-b pathology is known to modulate cholinergic activity in the cortex by altering neurotrophic signalling in Alzheimer’s disease (Yaar et al., 1997; Bulbarelli et al., 2009).”
BackgroundDiffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease.
Joachim, C. L., Morris, J. H., & Selkoe, D. J. (1989) · PubMed Central · Cited by 335
Lehmann, M., Ghosh, P. M., Madison, C., Laforce, R., Corbetta-Rastelli, C., Weiner, M. W., Greicius, M. D., Seeley, W. W., Gorno-Tempini, M. L., Rosen, H. J., et al. (2013) · Brain · doi:10.1093/brain/aws327 · Cited by 325 · cited 2×
“This finding supports ante-mortem PiB-PET studies that demonstrate amyloid-b binding is widely distributed in sporadic Alzheimer’s disease without focal involvement (Lehmann et al., 2013; Laforce et al., 2014)—with the exception of cases with posterior cortical atrophy (Crutch et al.”
BackgroundResultPIB is a non-specific imaging marker of amyloid-beta (A ) peptide-related cerebral amyloidosis
Lockhart, A., Lamb, J. R., Osredkar, T., Sue, L. I., Joyce, J. N., Ye, L., Libri, V., Leppert, D., & Beach, T. G. (2007) · Brain · doi:10.1093/brain/awm191 · Cited by 302 · cited 7×
“, 1991), both of which have fibrillar forms of amyloid that bind the fluorescent analogue of PiB or radiolabelled PiB (Lockhart et al., 2007; Ikonomovic et al., 2008).”
BackgroundMethodInfluentialLongitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [ 11 C]PiB
Resnick, S. M., Sojkova, J., Zhou, Y., An, Y., Ye, W., Holt, D. P., Dannals, R. F., Mathis, C. A., Klunk, W. E., Ferrucci, L., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d3e3e9 · Cited by 288 · cited 1×
“A longitudinal PiB study in individuals without dementia shows that higher PiB retention associates with cognitive decline in verbal memory, thus tracking well with disease progression (Resnick et al., 2010).”
BackgroundSenile Dementia of the Alzheimer Type Without Neocortical Neurofibrillary Tangles
TERRY, R. D., HANSEN, L. A., DETERESA, R., DAVIES, P., TOBIAS, H., & KATZMAN, R. (1987) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-198705000-00003 · Cited by 268 · cited 1×
“A standardized dissection and sampling method was used as described previously (Terry et al., 1987).”
MethodThe influence of education, social class and sex on Mini-Mental State scores
O'connor, D. W., Pollitt, P. A., Treasure, F. P., Brook, C. P. B., & Reiss, B. B. (1989) · Psychological Medicine · doi:10.1017/s0033291700024375 · Cited by 242
Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias
Murray, M. E., Kouri, N., Lin, W.-L., Jack, C. R., Dickson, D. W., & Vemuri, P. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt231 · Cited by 236 · cited 1×
“Alzheimer’s disease is a multi-proteinopathy, involving both extracellular amyloid-b deposits (i.e. amyloid-b plaques) and intracellular accumulation of post-translationally modified tau proteins [i.e. neurofibrillary tangles (NFT)], recently reviewed by Murray et al. (2014).”
BackgroundSelf-citationAssessment of β-amyloid deposits in human brain: a study of the BrainNet Europe Consortium
Alafuzoff, I., Thal, D. R., Arzberger, T., Bogdanovic, N., Al-Sarraj, S., Bodi, I., Boluda, S., Bugiani, O., Duyckaerts, C., Gelpi, E., et al. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0485-4 · Cited by 193
Multimodality imaging characteristics of dementia with Lewy bodies
Kantarci, K., Lowe, V. J., Boeve, B. F., Weigand, S. D., Senjem, M. L., Przybelski, S. A., Dickson, D. W., Parisi, J. E., Knopman, D. S., Smith, G. E., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.09.024 · Cited by 174
Self-citationModeling the Relation Between Neurofibrillary Tangles and Intellectual Status
Duyckaerts, C. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)80306-5 · Cited by 150 · cited 3×
“…recommendations for post-mortem diagnosis of Alzheimer’s disease, and is widely validated by clinicopathological studies that demonstrate strong associations with greater severity of cognitive decline (Duyckaerts et al., 1997; Bennett et al., 2004; Sabbagh et al., 2010; Nelson et al., 2012).”
BackgroundTau, amyloid, and hypometabolism in a patient with posterior cortical atrophy
Ossenkoppele, R., Schonhaut, D. R., Baker, S. L., O'Neil, J. P., Janabi, M., Ghosh, P. M., Santos, M., Miller, Z. A., Bettcher, B. M., Gorno‐Tempini, M. L., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24321 · Cited by 146
Incidence of cerebrovascular lesions in Alzheimer's disease: a postmortem study
Jellinger, K. A., & Attems, J. (2003) · Acta Neuropathologica · doi:10.1007/s00401-002-0634-5 · Cited by 133 · cited 1×
“The presence of significant vascular disease was based on Jellinger and Attems (2003) incidence study.”
BackgroundJanocko, N. J., Brodersen, K. A., Soto-Ortolaza, A. I., Ross, O. A., Liesinger, A. M., Duara, R., Graff-Radford, N. R., Dickson, D. W., & Murray, M. E. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1044-y · Cited by 126 · cited 1×
“(Janocko et al., 2012).”
Self-citationSojkova, J., Driscoll, I., Iacono, D., Zhou, Y., Codispoti, K.-E., Kraut, M. A., Ferrucci, L., Pletnikova, O., Mathis, C. A., Klunk, W. E., et al. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.357 · Cited by 113 · cited 4×
“Our study supports findings of variable agreement between CERAD ‘neuritic’ plaque score and in vivo PiB binding (Sojkova et al., 2011).”
MethodResultInfluentialDriscoll, I., Troncoso, J. C., Rudow, G., Sojkova, J., Pletnikova, O., Zhou, Y., Kraut, M. A., Ferrucci, L., Mathis, C. A., Klunk, W. E., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1025-1 · Cited by 104 · cited 4×
“The relationship between the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) ‘neuritic’ plaque score and ante-mortem PiB-PET imaging shows a range between moderate to high agreement (Sojkova et al., 2011; Driscoll et al., 2012).”
MethodInfluentialIn vivo assessment of amyloid‐β deposition in nondemented very elderly subjects
Mathis, C. A., Kuller, L. H., Klunk, W. E., Snitz, B. E., Price, J. C., Weissfeld, L. A., Rosario, B. L., Lopresti, B. J., Saxton, J. A., Aizenstein, H. J., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23797 · Cited by 98 · cited 2×
“…now been many studies of the association between cognition and amyloid-b accumulation at different points along the Alzheimer’s disease spectrum (Morris et al., 1996; Schmitt et al., 2000; Knopman et al., 2003; Petersen et al., 2006; Price et al., 2009; Maarouf et al., 2011; Mathis et al., 2013).”
BackgroundMaarouf, C. L., Daugs, I. D., Kokjohn, T. A., Walker, D. G., Hunter, J. M., Kruchowsky, J. C., Woltjer, R., Kaye, J., Castaño, E. M., Sabbagh, M. N., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027291 · Cited by 80 · cited 2×
“…now been many studies of the association between cognition and amyloid-b accumulation at different points along the Alzheimer’s disease spectrum (Morris et al., 1996; Schmitt et al., 2000; Knopman et al., 2003; Petersen et al., 2006; Price et al., 2009; Maarouf et al., 2011; Mathis et al., 2013).”
BackgroundSabbagh, M. N., Cooper, K., DeLange, J., Stoehr, J. D., Thind, K., Lahti, T., Reisberg, B., Sue, L., Vedders, L., Fleming, S. R., et al. (2010) · Current Alzheimer Research · doi:10.2174/156720510791162340 · Cited by 79 · cited 3×
“…recommendations for post-mortem diagnosis of Alzheimer’s disease, and is widely validated by clinicopathological studies that demonstrate strong associations with greater severity of cognitive decline (Duyckaerts et al., 1997; Bennett et al., 2004; Sabbagh et al., 2010; Nelson et al., 2012).”
BackgroundParallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology
Laforce, R., Tosun, D., Ghosh, P., Lehmann, M., Madison, C. M., Weiner, M. W., Miller, B. L., Jagust, W. J., & Rabinovici, G. D. (2014) · NeuroImage: Clinical · doi:10.1016/j.nicl.2014.03.005 · Cited by 73
Ante mortem amyloid imaging and β-amyloid pathology in a case with dementia with Lewy bodies
Kantarci, K., Yang, C., Schneider, J. A., Senjem, M. L., Reyes, D. A., Lowe, V. J., Barnes, L. L., Aggarwal, N. T., Bennett, D. A., Smith, G. E., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.08.007 · Cited by 70 · cited 5×
“PET imaging was performed in Mayo Clinic Rochester using the 11C amyloid tracer PiB with four 5-min dynamic frames acquired 40–60 min after injection, as previously described (Jack et al., 2008; Kantarci et al., 2012a).”
MethodInfluentialSelf-citationFocal hemosiderin deposits and β‐amyloid load in the ADNI cohort
Kantarci, K., Gunter, J. L., Tosakulwong, N., Weigand, S. D., Senjem, M. S., Petersen, R. C., Aisen, P. S., Jagust, W. J., Weiner, M. W., Jack, C. R., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.10.011 · Cited by 66 · cited 1×
“…amyloid angiopathy in the occipital lobe, visual grading of PiB-PET scans should be performed with the concept that greater occipital-to-global PiB ratio may occur in patients with Alzheimer’s disease dementia with suspected cerebral amyloid angiopathy (Johnson et al., 2007; Kantarci et al., 2013).”
BackgroundSelf-citationPerez, S. E., He, B., Nadeem, M., Wuu, J., Scheff, S. W., Abrahamson, E. E., Ikonomovic, M. D., & Mufson, E. J. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.12.016 · Cited by 47 · cited 1×
“Increasing evidence, however, suggests that neurotrophic signalling is not affected by amyloid-b pathology in the prodromal stages of Alzheimer’s disease dementia (Perez et al., 2015).”
BackgroundMurray, M. E., & Dickson, D. W. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt254 · Cited by 40 · cited 2×
“Thal amyloid Phase 1–2 cases with sufficient plaques for Alzheimer’s disease diagnosis, 155 are Braak NFT stage 5IV (i.e. pathological ageing cases) (Murray and Dickson, 2014) and only 29 are Braak 5IV (i.e. advanced Alzheimer’s disease cases).”
BackgroundSelf-citationPittsburgh compound B and the postmortem diagnosis of alzheimer disease
Niedowicz, D. M., Beckett, T. L., Matveev, S., Weidner, A. M., Baig, I., Kryscio, R. J., Mendiondo, M. S., LeVine, H., Keller, J. N., & Murphy, M. P. (2012) · Annals of Neurology · doi:10.1002/ana.23633 · Cited by 38 · cited 3×
“There is evidence, however, that PiB binds to diffuse plaques, as well as cerebral amyloid angiopathy in the vessels and parenchyma (Johnson et al., 2007; Lockhart et al., 2007; Ikonomovic et al., 2008; Niedowicz et al., 2012).”
BackgroundTrkA pathway activation induced by amyloid-beta (Abeta)
Bulbarelli, A., Lonati, E., Cazzaniga, E., Re, F., Sesana, S., Barisani, D., Sancini, G., Mutoh, T., & Masserini, M. (2008) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2008.12.006 · Cited by 35 · cited 1×
“Amyloid-b pathology is known to modulate cholinergic activity in the cortex by altering neurotrophic signalling in Alzheimer’s disease (Yaar et al., 1997; Bulbarelli et al., 2009).”
BackgroundPrice (1999) · doi:10.1002/1531-8249(199903)45:3
Research works printed but not linked: 1
- 10.1002/1531-8249(199903)45:3<358::aid-ana12>3.0.co;2-x · doi:10.1002/1531-8249(199903)45:3<358::aid-ana12>3.0.co;2-x
Cited by
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
“A typical cut point used for (11)C Pittsburgh compound B approximately labels individuals with Thal phase 0–1 normal and individuals with Thal phase 2–5 abnormal [21].”
Self-citationAlzheimer Disease Genetics Consortium (ADGC), Kunkle, B. W., The European Alzheimer’s Disease Initiative (EADI), Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium (CHARGE), Genetic and Environmental Risk in AD/Defining Genetic, P. A. E. R. F. A. D. C. (., Grenier-Boley, B., Sims, R., Bis, J. C., Damotte, V., Naj, A. C., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0358-2 · Cited by 2,946
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Jack, C. R., Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., Graf, A., Hansson, O., Ho, C., Jagust, W., McDade, E., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13859 · Cited by 2,803
Self-citationKnopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00269-y · Cited by 2,606
Self-citationPreclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925
“Fewer studies have correlated PET with Thal amyloid staging, suggesting earliest detection around stage 1 [66,70].”
BackgroundSelf-citation
Metadata
- Authors
- Murray, M. E., Lowe, V. J., Graff-Radford, N. R., Liesinger, A. M., Cannon, A., Przybelski, S. A., Rawal, B., Parisi, J. E., Petersen, R. C., Kantarci, K., Ross, O. A., Duara, R., Knopman, D. S., Jack, C. R., & Dickson, D. W.
- Affiliations
- Mayo Clinic (US)
- University of Miami (US)
- Corresponding author
- Murray, Melissa E.
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-03-23
- Volume
- 138
- Issue
- 5
- Pages
- 1370-1381
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC4407190
- OpenAlex
- W2148457471
- Cited by
- 324
- References
- 72
- Citations by year
- 2026: 9 · 2025: 18 · 2024: 22 · 2023: 15 · 2022: 18 · 2021: 32 · 2020: 38 · 2019: 41 · 2018: 34 · 2017: 36 · 2016: 35 · 2015: 25
- FWCI
- 35.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Brain (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Alzheimer's Association
- National Institute on Aging (R01AG040042, U01AG006786, R01AG011378, R01AG041851, P50AG016574)
- National Institute of Neurological Disorders and Stroke (P50NS072187)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, 11C-Pittsburgh compound B, amyloid PET, amyloid plaques, APOE ε4, cerebral amyloid angiopathy, thioflavin S staining, age of onset, disease duration, amyloid biomarkers
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Amyloid, Aniline Compounds, Female, Humans, Male, Middle Aged, Thiazoles, Amyloid beta-Peptides, Positron-Emission Tomography, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.